Somnath Sarkar

TL;DR: The present data show that the measured BMD changes observed with raloxifene therapy are poor predictors of vertebral fracture risk reduction with rAloxifenes, and this work concludes that women with the lowest baseline BMD in the MORE cohort had the greatest risk for vertebral fractures.

TL;DR: The relationship between change in bone turnover and vertebral fracture risk during raloxifene therapy using 3-year data from the MORE trial, where 2622 of the 7705 randomized women had measurement of bone markers at baseline and after 6 and 12 months participation, is studied.

TL;DR: The mean cognitive scores in the three groups of women were similar at base line, and the scores improved slightly in all three groups during the three-year study peri...

TL;DR: The change in BMD is a poor predictor of vertebral fracture risk after raloxifene treatment, but the percent change in osteocalcin was determined to be a better predictor of spinal fracture risk than BMD.

TL;DR: Raloxifene at a dose of 120 mg/day, but not 60 mg/days, resulted in reduced risk of cognitive impairment in postmenopausal women.